Journal of Hepatology
Volume 52, Issue 3 , Pages 441-449 , March 2010

Is response to antiviral treatment influenced by hepatitis B virus genotype?

  • Sara Raimondi

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    • ,
  • Patrick Maisonneuve

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    • ,
  • Savino Bruno

      Affiliations

    • Liver Unit, Department of Medicine, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy
    • ,
  • Mario U. Mondelli

      Affiliations

    • Research Laboratories, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Via Taramelli 5, 27100 Pavia, Italy. Tel.: +39 0382 502630; fax: +39 0382 526450.

Received 19 August 2009 ,Revised 25 September 2009 ,Accepted 2 October 2009.

References 

  1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352
  2. Liang TJ. Hepatitis B: the virus and the disease. Hepatology. 2009;49(Suppl.):S13–S21
  3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374
  4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  5. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35:1274–1276
  6. In:  Mason WS,  Burrell CJ,  Casey J,  Gerlich WH,  Howard CR,  Kann M, et al. editor. Virus taxonomy. Eighth report of the international committee on taxonomy of viruses. Amsterdam: Elsevier; 2005;
  7. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol. 2007;13:14–21
  8. Hannoun C, Krogsgaard K, Horal P, Lindh M. Group tIT. Genotype mixtures of hepatitis B virus in patients treated with interferon. J Infect Dis. 2002;186:752–759
  9. Kao JH, Chen PJ, Lai MY, Chen DS. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology. 2001;34:817–823
  10. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol. 2002;76:5985–5992
  11. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–559
  12. Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S, Koike K. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology. 2001;120:1564–1565
  13. Taylor Brent C, Yuan Jian-Min, Shamliyan Tatyana A, Shaukat Aasma, Kane Robert L, Wilt Timothy J. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology. 2009;49:S85–S95
  14. Yu MW, Yeh SH, Chen PJ, LiawY F, Lin CL, Liu CJ, et al. Genotype and DNA levels of hepatitis B virus and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:265–272
  15. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195:5–11
  16. Sorrell Michael F, Belongia Edward A, Costa Jose, Gareen Ilana F, Grem Jean L, Inadomi John M. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49:S4–S12
  17. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HLA. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297–303
  18. Buster EHCJ, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology. 2008;135:459–467
  19. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from the explorative analysis of published evidence. Antivir Ther. 2008;13:211–220
  20. Erhardt A, Ludwig AD, Brunetto M, van Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract]. Hepatology. 2008;48(Suppl.):700A
  21. Hou J, Schilling R, Janssen HLA, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055–1063
  22. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006;6:417–423
  23. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  24. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–454
  25. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455
  26. Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776–2783
  27. Westland C, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003;125:107–116
  28. Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46:388–394
  29. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. N Engl J Med. 2005;352:2682–2695
  30. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11–20
  31. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541–548
  32. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129
  33. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699–705
  34. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495
  35. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99–108
  36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–1751
  37. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009;50:1084–1092

PII: S0168-8278(09)00815-0

doi: 10.1016/j.jhep.2009.12.014

Journal of Hepatology
Volume 52, Issue 3 , Pages 441-449 , March 2010

Article Tools